RxDoctor Payments DataLook up a doctor →

Vince Vismara, MD

Interventional Cardiology · Columbia, SCNPI 1285691931

Payments from drug & device makers

$142,252in general payments, 2019–2025

Across 1,048 payments — averaging $135.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$80K
  • Boston Scientific$20K
  • Recor Medical Inc$9K
  • Abbott$6K
  • Edwards Lifesciences$4K
  • Medtronic$4K
  • plus $20K from 45 others

What the payments were for

  • Consulting fees$13,25022%
  • Speaking & faculty fees$4,0007%
  • Travel & lodging$10,94318%
  • Food & beverage$31,10952%
  • Other$2820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,252 in reported general payments places this provider in the 85th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$256,525
Medicare patients
1,092
Services billed
3,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$86,080
Repatha SureclickEvolocumab71$56,671
EntrestoSacubitril/Valsartan19$26,746
XareltoRivaroxaban23$17,977
JardianceEmpagliflozin11$9,831
Valsartan86$2,653
Ezetimibe85$2,135
Metoprolol Succinate109$1,898
Rosuvastatin Calcium86$1,603
Telmisartan35$1,326
Carvedilol97$1,092
Atorvastatin Calcium73$954
Prasugrel Hcl28$948
Losartan Potassium21$648
Amlodipine Besylate76$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$497$86,08070 claims
NovartisEntresto$1,705$26,74619 claims
Johnson & JohnsonXarelto$247$17,97723 claims
Boehringer IngelheimJardiance$377$9,83111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →